Artículo
Bevacqua, R.J.; Perrone, S.V. "In search of the Holy Grail clinical, pharmacological and haemodynamic effects of Serelaxin in acute heart failure " (2014) Insuficiencia Cardiaca. 9(4):192-197
Estamos trabajando para incorporar este artículo al repositorio
Consulte la política de Acceso Abierto del editor
Abstract:
Acute heart failure (AHF) is a heterogeneous clinical syndrome and severe threatening the patient’s life, with worldwide increasing prevalence and presenting very high healthcare costs. However in recent times, been little progress on this topic. Despite extensive research effort, there has been no significant pharmacological advance in the management of AHF patients with respect to mortality and symptoms relief for several decades. Serelaxin is a recombinant form of human relaxin-2, a peptide hormone of natural origin. Relaxin-2 occurs naturally in women is a mediator of maternal systemic hemodynamics and renal adaptations to an increase in intravascular volume during pregnancy. Relaxin-2 exerts numerous hemodynamic and renal effects in pregnant women, such as increase in arterial compliance with concomitant fall in systemic vascular resistance, and increase in renal blood flow, glomerular filtration rate, and cardiac output. In studies to date, serelaxin was well tolerated with no apparent safety concerns and exerted favorable haemodynamic effects on pulmonary capillary pressure and pulmonary arterial pressure, but did not significantly change cardiac index, in patients with AHF and normal to high systolic blood pressure. The hemodynamic effects of serelaxin observed in studies provide important support for plausible improvement in signs and symptoms of congestion observed in patients with AHF. Serelaxin is a promising drug for the treatment of AHF. © 2014 Silver Horse.
Registro:
| Documento: | Artículo |
| Título: | In search of the Holy Grail clinical, pharmacological and haemodynamic effects of Serelaxin in acute heart failure |
| Autor: | Bevacqua, R.J.; Perrone, S.V. |
| Filiación: | Division Cardiologia, Pabellon Inchauspe. Hospital General de Agudos, Dr. Jose Maria Ramos Mejia, Buenos Aires, Argentina Insuficiencia cardiaca, Hipertension pulmonar. Trasplante cardiaco, Instituto FLENI, Buenos Aires, Argentina Instituto Argentino de Diagnostico y Tratamiento, Buenos Aires, Argentina Hospital Alta Complejidad en Red El Cruce, Dr. Nestor Carlos Kirchner, Florencio Varela, Buenos Aires, Argentina Instituto Cardiovascular Lezica, San Isidro, Buenos Aires, Argentina Hospital Italiano de Mendoza, Mendoza, Argentina |
| Palabras clave: | Acute heart failure; Clinical trials; Hemodynamic; Serelaxin |
| Año: | 2014 |
| Volumen: | 9 |
| Número: | 4 |
| Página de inicio: | 192 |
| Página de fin: | 197 |
| Título revista: | Insuficiencia Cardiaca |
| Título revista abreviado: | Insuficiencia Cardiaca |
| ISSN: | 18501044 |
| Registro: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v9_n4_p192_Bevacqua |
Referencias:
- Gheorghiade, M., Pang, P.S., Acute heart failure syndromes (2009) J am Coll Cardiol, 53, pp. 557-573
- Fang, J., Mensah, G.A., Croft, J.B., Keenan, N.L., Heart failurerelated hospitalization in the US, 1979 to 2004 (2008) J am Coll Cardiol, 52, pp. 428-434
- McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., Falk, V., Ponikowski, P., Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC (2012) Eur Heart J, 33, pp. 1787-1847
- Conrad, K.P., Maternal vasodilation in pregnancy: The emerging role of relaxin (2011) Am J Physiol Regul Integr Comp Physiol, 301, pp. R267-R275
- Teichman, S.L., Unemori, E., Teerlink, J.R., Cotter, G., Metra, M., Relaxin: Review of biology and potential role in treating heart failure (2010) Curr Heart Fail Rep, 7, pp. 75-82
- Dschietzig, T., Teichman, S., Unemori, E., Wood, S., Boehmer, J., Richter, C., Baumann, G., Stangl, K., Intravenous recombinant human relaxin in compensated heart failure: A safety, tolerability, and pharmacodynamic trial (2009) J Card Fail, 15, pp. 182-190
- Du, X.J., Bathgate, R.A., Samuel, C.S., Dart, A.M., Summers, R.J., Cardiovascular effects of relaxin: From basic science to clinical therapy (2010) Nat Rev Cardiol, 7, pp. 48-58
- Teerlink, J.R., Metra, M., Felker, G.M., Ponikowski, P., Voors, A.A., Weatherley, B.D., Marmor, A., Cotter, G., Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study (2009) Lancet, 373, pp. 1429-1439
- Teerlink, J.R., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., Ponikowski, P., Metra, M., Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial (2013) Lancet, 381, pp. 29-39
- Hernandez, A., Serelaxin: Insights into its haemodynamic, biochemical, and clinical effects in acute heart failure (2014) Eur Heart J, 35, pp. 410-412
- Teerlink, J.R., Metra, M., Felker, G.M., Ponikowski, P., Voors, A.A., Weatherley, B.D., Marmor, A., Cotter, G., Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study (2009) Lancet, 373, pp. 1429-1439
- Teerlink, J.R., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., Ponikowski, P., Metra, M., RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebocontrolled trial (2013) Lancet, 381, pp. 29-39
- Metra, M., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., Ponikowski, P., Teerlink, J.R., RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. Correlation with outcomes (2013) J am Coll Cardiol, 61, pp. 196-206
- Ponikowski, P., Mitrovic, V., Ruda, M., Fernandez, A., Voors, A.A., Vishnevsky, A., Cotter, G., Metra, M., A randomized, doubleblind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure (2014) Eur Heart J, 35, pp. 431-441
- Metra, M., Teerlink, J.R., Voors, A.A., Felker, G.M., Milo-Cotter, O., Weatherley, B., Dittrich, H., Cotter, G., Vasodilators in the treatment of acute heart failure: What we know, what we don’t (2009) Heart Fail Rev, 14, pp. 299-307
- Publication Committee for the VMAC Investigators, Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure (2002) JAMA, 287, pp. 1531-1540
- Mitrovic, V., Seferovic, P.M., Simeunovic, D., Ristic, A.D., Miric, M., Moiseyev, V.S., Kobalava, Z., Meyer, M., Haemodynamic and clinical effects of ularitide in decompensated heart failure (2006) Eur Heart J, 27, pp. 2823-2832
- O’Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., Heizer, G.M., Califf, R.M., Effect of nesiritide in patients with acute decompensated heart failure (2011) N Engl J Med, 365, pp. 32-43
- Metra, M., Ponikowski, P., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., Teerlink, J.R., Effects of serelaxin in subgroups of patients with acute heart failure: Results fromRELAX-AHF (2013) Eur Heart J, 34, pp. 3128-3136
- Hernandez, A.V., Boersma, E., Murray, G.D., Habbema, J., Steyerberg, E.W., Subgroup analysis in therapeutic cardiovascular clinical trials: Are most of them misleading? (2006) Am Heart J, 151, pp. 257-264
- (2014), http://www.novartis.com/newsroom/media-releases/en/2013/1711047.shtml, February
Citas:
---------- APA ----------
Bevacqua, R.J. & Perrone, S.V. (2014) . In search of the Holy Grail clinical, pharmacological and haemodynamic effects of Serelaxin in acute heart failure . Insuficiencia Cardiaca, 9(4), 192-197.Recuperado de https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v9_n4_p192_Bevacqua [ ]
---------- CHICAGO ----------
Bevacqua, R.J., Perrone, S.V. "In search of the Holy Grail clinical, pharmacological and haemodynamic effects of Serelaxin in acute heart failure " . Insuficiencia Cardiaca 9, no. 4 (2014) : 192-197.Recuperado de https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v9_n4_p192_Bevacqua [ ]
---------- MLA ----------
Bevacqua, R.J., Perrone, S.V. "In search of the Holy Grail clinical, pharmacological and haemodynamic effects of Serelaxin in acute heart failure " . Insuficiencia Cardiaca, vol. 9, no. 4, 2014, pp. 192-197.Recuperado de https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v9_n4_p192_Bevacqua [ ]
---------- VANCOUVER ----------
Bevacqua, R.J., Perrone, S.V. In search of the Holy Grail clinical, pharmacological and haemodynamic effects of Serelaxin in acute heart failure . Insuficiencia Cardiaca. 2014;9(4):192-197.Available from: https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v9_n4_p192_Bevacqua [ ]
